Taro Historical Income Statement
| TARO Stock | USD 42.73 0.01 0.02% |
Historical analysis of Taro Pharmaceutical income statement accounts such as EBIT of 20.4 M, Ebitda of 50 M, Cost Of Revenue of 340.4 M or Total Operating Expenses of 297.6 M can show how well Taro Pharmaceutical Industries performed in making a profits. Evaluating Taro Pharmaceutical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Taro Pharmaceutical's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Taro Pharmaceutical latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Taro Pharmaceutical is a good buy for the upcoming year.
Taro |
About Taro Income Statement Analysis
Taro Pharmaceutical Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Taro Pharmaceutical shareholders. The income statement also shows Taro investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Taro Pharmaceutical Income Statement Chart
Add Fundamental
Total Revenue
Total revenue comprises all receipts Taro Pharmaceutical generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Gross Profit
Gross profit is a required income statement account that reflects total revenue of Taro Pharmaceutical Industries minus its cost of goods sold. It is profit before Taro Pharmaceutical operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Taro Pharmaceutical. It is also known as Taro Pharmaceutical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Operating Income
Operating Income is the amount of profit realized from Taro Pharmaceutical operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Taro Pharmaceutical Industries is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most accounts from Taro Pharmaceutical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Taro Pharmaceutical current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taro Pharmaceutical Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. At this time, Taro Pharmaceutical's Net Income is very stable compared to the past year. As of the 17th of June 2024, Interest Expense is likely to grow to about 21.4 M, while Total Revenue is likely to drop about 365.8 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 293.1M | 268.3M | 305.0M | 238.5M | Total Revenue | 561.3M | 573.0M | 629.2M | 365.8M |
Taro Pharmaceutical income statement Correlations
Click cells to compare fundamentals
Taro Pharmaceutical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Taro Pharmaceutical income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Revenue | 644.8M | 549.0M | 561.3M | 573.0M | 629.2M | 365.8M | |
| Gross Profit | 399.7M | 296.7M | 293.1M | 268.3M | 305.0M | 238.5M | |
| Other Operating Expenses | 398.2M | 403.8M | 436.4M | 555.2M | 607.7M | 638.1M | |
| Operating Income | 246.5M | 704.4M | 184.4M | 17.7M | 21.5M | 20.4M | |
| Ebit | 246.5M | 704.4M | 184.4M | 17.7M | 21.5M | 20.4M | |
| Ebitda | 253.1M | 728.1M | 210.3M | 52.7M | 52.6M | 50.0M | |
| Cost Of Revenue | 245.0M | 252.3M | 268.2M | 304.6M | 324.2M | 340.4M | |
| Total Operating Expenses | 153.2M | 151.5M | 168.2M | 250.6M | 283.5M | 297.6M | |
| Income Before Tax | 298.0M | (391.1M) | 77.9M | 38.2M | 82.7M | 113.5M | |
| Total Other Income Expense Net | 51.5M | (1.1B) | (106.5M) | 20.5M | 61.2M | 64.2M | |
| Income Tax Expense | 53.5M | 9.7M | 19.6M | 12.8M | 28.8M | 24.2M | |
| Depreciation And Amortization | 6.5M | 23.7M | 25.9M | 34.9M | 31.1M | 32.6M | |
| Net Income | 244.2M | (400.7M) | 58.3M | 25.4M | 53.9M | 91.1M | |
| Research Development | 59.8M | 60.2M | 54.5M | 52.2M | 64.5M | 45.9M | |
| Interest Expense | 725K | 1.4M | 1.7M | 17.7M | 20.3M | 21.4M | |
| Selling General Administrative | 56.8M | 52.8M | 57.1M | 85.1M | 97.8M | 83.4M | |
| Net Income Applicable To Common Shares | 281.8M | 244.2M | (386.7M) | 58.3M | 67.0M | 63.7M | |
| Minority Interest | 5.2M | 5.6M | 5.9M | (8.2M) | (904K) | 0.0 | |
| Selling And Marketing Expenses | 36.7M | 38.5M | 56.6M | 113.3M | 130.3M | 136.8M | |
| Net Income From Continuing Ops | 244.6M | (400.7M) | 58.3M | 25.4M | 22.9M | 21.8M | |
| Tax Provision | 53.5M | 9.7M | 19.6M | 12.8M | 11.5M | 10.9M | |
| Interest Income | 22.7M | 20.2M | 8.2M | 20.9M | 18.8M | 14.6M | |
| Net Interest Income | 33.6M | 20.2M | 8.2M | 20.9M | 18.8M | 17.2M | |
| Reconciled Depreciation | 21.4M | 23.7M | 25.9M | 32.1M | 36.9M | 25.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectAdditional Information and Resources on Investing in Taro Stock
When determining whether Taro Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Taro Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Taro Pharmaceutical Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Taro Pharmaceutical Industries Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Taro Pharmaceutical Industries. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Taro Pharmaceutical. If investors know Taro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Taro Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.181 | Earnings Share 1.43 | Revenue Per Share 16.74 | Quarterly Revenue Growth 0.125 | Return On Assets 0.0021 |
The market value of Taro Pharmaceutical is measured differently than its book value, which is the value of Taro that is recorded on the company's balance sheet. Investors also form their own opinion of Taro Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Taro Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Taro Pharmaceutical's market value can be influenced by many factors that don't directly affect Taro Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Taro Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Taro Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Taro Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.